Endocyte Back On Track To File Lead Candidate For EU Conditional Approval This Year
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The U.S. biotech, which went public last year, plans to file EC145 and a companion diagnostic for conditional approval in Europe in platinum-resistant ovarian cancer in the third quarter, based on findings from four Phase I and Phase II trials.